GT Biopharma Inc Asset Resilience Ratio
GT Biopharma Inc asset resilience ratio. GT Biopharma Inc (GTBP) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of GT Biopharma Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of GT Biopharma Inc (2005–2024)
Asset resilience ratio of GT Biopharma Inc from 2005 to 2024. This chart shows how GT Biopharma Inc's Asset Resilience Ratio has changed over time. Read GTBP total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down GT Biopharma Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see GT Biopharma Inc balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: GT Biopharma Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
GT Biopharma Inc Industry Peers by Asset Resilience Ratio
Compare GT Biopharma Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
GT Biopharma Inc Asset Resilience Ratio by Year (2005–2024)
GT Biopharma Inc asset resilience ratio by year from 2005 to 2024. The table below shows the annual Asset Resilience Ratio data for GT Biopharma Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | $0.00 | $4.23 Million | -- |
| 2023-12-31 | 91.38% | $12.89 Million | $14.11 Million | +26.63pp |
| 2022-12-31 | 64.75% | $10.84 Million | $16.74 Million | -6.78pp |
| 2021-12-31 | 71.53% | $23.01 Million | $32.17 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $5.66 Million | -- |
| 2006-12-31 | 38.26% | $3.06 Million | $8.00 Million | -0.94pp |
| 2005-12-31 | 39.20% | $3.06 Million | $7.81 Million | -- |
About GT Biopharma Inc
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, tha… Read more